Intravenous Injection of Apolipoprotein A-V Reconstituted High-Density Lipoprotein Decreases Hypertriglyceridemia in apoav −/− Mice and Requires Glycosylphosphatidylinositol-Anchored High-Density Lipoprotein–Binding Protein 1 | Zendy

Xiao Shu | Zendy; Lisa Nelbach | Zendy; Michael M. Weinstein | Zendy; Braydon L. Burgess | Zendy; Jennifer A. Beckstead | Zendy; Stephen G. Young | Zendy; Robert O. Ryan | Zendy; Trudy M. Forte | Zendy

Open Access

Intravenous Injection of Apolipoprotein A-V Reconstituted High-Density Lipoprotein Decreases Hypertriglyceridemia in apoav −/− Mice and Requires Glycosylphosphatidylinositol-Anchored High-Density Lipoprotein–Binding Protein 1

Author(s) -

Xiao Shu,

Lisa Nelbach,

Michael M. Weinstein,

Braydon L. Burgess,

Jennifer A. Beckstead,

Stephen G. Young,

Robert O. Ryan,

Trudy M. Forte

Publication year - 2010

Publication title -

arteriosclerosis thrombosis and vascular biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.007

H-Index - 270

eISSN - 1524-4636

pISSN - 1079-5642

DOI - 10.1161/atvbaha.110.210815

Subject(s) - hypertriglyceridemia , very low density lipoprotein , medicine , endocrinology , apolipoprotein b , lipoprotein , chemistry , in vivo , cholesterol , phospholipid , knockout mouse , biology , triglyceride , biochemistry , receptor , microbiology and biotechnology , membrane

Apolipoprotein A-V (apoA-V), a minor protein associated with lipoproteins, has a major effect on triacylglycerol (TG) metabolism. We investigated whether apoA-V complexed with phospholipid in the form of a reconstituted high-density lipoprotein (rHDL) has potential utility as a therapeutic agent for treatment of hypertriglyceridemia (HTG) when delivered intravenously.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research